Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

Core Insights - Cellectar Biosciences has entered a multi-year supply agreement with Ionetix Corporation for the provision of Actinium-225 (Ac-225) and Astatine-211 (At-211) to support its cancer treatment development programs [1][2] Group 1: Agreement Details - Ionetix will supply Cellectar with cGMP-grade Ac-225 and At-211 for clinical trials and potential commercial launches of targeted alpha therapy (TAT) candidates [2] - The collaboration aims to ensure a reliable and scalable supply of high-quality alpha-emitting isotopes essential for Cellectar's targeted phospholipid radioconjugate (PRC) pipeline [3] Group 2: Technology and Development - Cellectar's proprietary phospholipid ether platform technology allows for effective delivery of isotopes directly to tumor cells, enhancing treatment efficacy for various cancers [3] - Ac-225 and At-211 are identified as ideal isotopes for localized, high-energy radiation treatment, which can destroy tumors while minimizing damage to surrounding healthy tissue [3] Group 3: Future Expansion - Cellectar is preparing to expand its radiotherapeutic pipeline beyond current clinical programs, with CLR-225 being advanced into clinical trials for challenging solid tumors like pancreatic cancer [3] - Ionetix is installing a second cyclotron to meet the growing demand for Ac-225 and At-211, which are critical for advancing Cellectar's next-generation TATs [4] Group 4: Company Overview - Cellectar Biosciences is a late-stage clinical radiopharmaceutical company focused on developing proprietary drugs for cancer treatment, leveraging its Phospholipid Drug Conjugate™ (PDC) delivery platform [5]